[8-K] Fortress Biotech, Inc. Reports Material Event

Rhea-AI Filing Summary

Analyzing...

0001429260false0001429260us-gaap:CommonStockMember2025-10-012025-10-010001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2025-10-012025-10-0100014292602025-10-012025-10-01

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 1, 2025

Fortress Biotech, Inc.

(Exact Name of Registrant as Specified in Charter)

​

Delaware
 (State or Other Jurisdiction
of Incorporation) 001-35366
 (Commission File Number) 20-5157386
(IRS Employer
Identification No.)

​

1111 Kane Concourse, Suite 301

Bay Harbor Islands, FL 33154

(Address of Principal Executive Offices)

(781) 652-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act.

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	FBIO	Nasdaq Capital Market
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock	FBIOP	Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 8.01.    Other Events.

​

On October 1, 2025, Fortress Biotech, Inc. issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter for CUTX-101 (copper histidinate). The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

​

Item 9.01.    Financial Statements and Exhibits.

​

(d)    Exhibits.

The following exhibit is furnished herewith:

99
Exhibit Number		Description
99.1 104	​	Press release of Fortress Biotech, Inc., dated October 1, 2025. Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	Fortress Biotech, Inc.
​	(Registrant)
​	​
Date: October 1, 2025
​	​	​
	By:	/s/ David Jin
		David Jin
		Chief Financial Officer

​

​

​

​

​